Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16026511 | 0.84 | ALDH1A1 (0.46) | ALDH1A1MAPTMAPK1GAATSHR | |
| SCHEMBL9423802 | 0.83 | ALDH1A1 (0.41) | ALDH1A1KDM4EMAPTGAA | |
| SCHEMBL14590618 | 0.79 | ALDH1A1 (0.51) | ALDH1A1KDM4EMAPTTDP1MAPK1 | |
| SCHEMBL8243898 | 0.73 | ALDH1A1 (0.38) | ALDH1A1KDM4E | |
| SCHEMBL5554701 | 0.69 | HSD17B10 (0.48) | ALDH1A1S1PR1MAPTTSHR | |
| SCHEMBL11747750 | 0.68 | ALDH1A1 (0.41) | ALDH1A1KDM4EMAPTMAPK1GAA | |
| Tetraxetan SCHEMBL5370171 | 0.67 | HSD17B10 (0.58) | ALDH1A1S1PR1KDM4EMAPTGAA | |
| SCHEMBL6848102 | 0.66 | HSD17B10 (0.64) | ALDH1A1S1PR1KDM4EMAPTMAPK1 | |
| Tetraxetan SCHEMBL18018 | 0.66 | HSD17B10 (0.64) | ALDH1A1S1PR1KDM4EMAPTMAPK1 | |
| SCHEMBL321989 | 0.66 | HSD17B10 (0.64) | ALDH1A1S1PR1KDM4EMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911457-B2 | Imaging probes and methods for using the probes in diagnostic imaging processes and other imaging processes to determine physiological functions. | CARBOMER, INC. (US) | 2005-06-28 | — | — | US | claimed |
| US-20030207823-A1 | Novel diabetes imaging probes | CARBOMER, INC. | 2003-11-06 | — | — | US | claimed |
| US-6911457-B2 | Imaging probes and methods for using the probes in diagnostic imaging processes and other imaging processes to determine physiological functions. | CARBOMER, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-20030207823-A1 | Novel diabetes imaging probes | CARBOMER, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003086563-A2 | DIABETES IMAGING PROBES | CARBOMER, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207823-A1 | Novel diabetes imaging probes | IAPP, GPR119, DPP4 | ALDH1A1 3199/4885S1PR1 837/4885KDM4E 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.